What are the recommended treatment regimens for chronic hepatitis C in adults, including options for different genotypes, cirrhosis status, and prior treatment experience?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment for Hepatitis C

Modern hepatitis C treatment uses all-oral direct-acting antiviral (DAA) regimens that achieve >95% cure rates across all genotypes, with treatment selection based primarily on genotype, cirrhosis status, and prior treatment experience.

First-Line Pangenotypic Regimens (Preferred)

The most recent EASL 2020 guidelines 1 establish pangenotypic regimens as the standard of care, eliminating the need for genotype testing in most settings:

For Patients WITHOUT Cirrhosis:

  • Sofosbuvir/velpatasvir: 12 weeks (all genotypes, treatment-naïve and experienced) 1
  • Glecaprevir/pibrentasvir: 8 weeks (all genotypes, treatment-naïve and experienced) 1

For Patients WITH Compensated Cirrhosis (Child-Pugh A):

  • Treatment-naïve: Either sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 8 weeks 1
  • Treatment-experienced: Sofosbuvir/velpatasvir for 12 weeks OR glecaprevir/pibrentasvir for 12 weeks 1

Critical caveat: Genotype 3 with cirrhosis requires special consideration (see below).

Genotype-Specific Considerations

While pangenotypic regimens work for most patients, certain genotypes require modified approaches:

Genotype 1 (Most Common in Western Countries)

Multiple highly effective options exist 2, 3:

  • Ledipasvir/sofosbuvir: 12 weeks (A1 recommendation)
  • Elbasvir/grazoprevir: 12 weeks (A1 recommendation)
  • Sofosbuvir/velpatasvir: 12 weeks (A1 recommendation)
  • Glecaprevir/pibrentasvir: 8 weeks without cirrhosis, 12 weeks with cirrhosis (A1 recommendation)

Genotype 2

Without cirrhosis:

  • Glecaprevir/pibrentasvir: 8 weeks (A1) 2
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 2
  • Sofosbuvir + ribavirin: 12 weeks (A1) 2

With compensated cirrhosis:

  • Glecaprevir/pibrentasvir: 12 weeks (A1) 2
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 2
  • Sofosbuvir + ribavirin: 16 weeks (B1) 2

Genotype 3 (Most Challenging)

This genotype requires the most careful attention, particularly with cirrhosis:

Treatment-naïve without cirrhosis:

  • Sofosbuvir/velpatasvir: 12 weeks 1
  • Glecaprevir/pibrentasvir: 8 weeks 1

Treatment-naïve WITH compensated cirrhosis (choose one):

  • Sofosbuvir/velpatasvir + weight-based ribavirin: 12 weeks (A1) 1
  • Sofosbuvir/velpatasvir/voxilaprevir: 12 weeks (A1) 1
  • Glecaprevir/pibrentasvir: 12 weeks (A1) 1

Treatment-experienced WITH compensated cirrhosis:

  • Sofosbuvir/velpatasvir + weight-based ribavirin: 12 weeks (A1) 1
  • Sofosbuvir/velpatasvir/voxilaprevir: 12 weeks (A1) 1
  • Glecaprevir/pibrentasvir: 16 weeks (A1) 1

The evidence shows genotype 3 with cirrhosis has historically lower SVR rates (58% in some early studies) 2, necessitating either ribavirin addition or extended duration.

Genotype 4

Multiple effective options 2:

  • Ledipasvir/sofosbuvir: 12 weeks (A1)
  • Elbasvir/grazoprevir: 12 weeks (A1)
  • Glecaprevir/pibrentasvir: 8 weeks without cirrhosis, 12 weeks with cirrhosis (A1)
  • Sofosbuvir/velpatasvir: 12 weeks (A1)
  • Ombitasvir/paritaprevir/ritonavir + ribavirin: 12 weeks (A1)

Genotypes 5 and 6

  • Ledipasvir/sofosbuvir: 12 weeks 2
  • Sofosbuvir/velpatasvir: 12 weeks 1
  • Glecaprevir/pibrentasvir: 8 weeks without cirrhosis, 12 weeks with cirrhosis 1

Treatment-Experienced Patients

For patients who failed prior DAA therapy, the approach depends on prior regimen:

Failed NS5A inhibitor-based regimen:

  • Sofosbuvir/velpatasvir/voxilaprevir is preferred for salvage therapy 1

Failed interferon-based regimen:

  • Treat as treatment-naïve with current DAA regimens 2

Decompensated Cirrhosis (Child-Pugh B/C)

This population requires specialized management 4:

  • Preferred: Sofosbuvir + NS5A inhibitor (ledipasvir or velpatasvir) ± ribavirin
  • Avoid: Protease inhibitor-containing regimens (contraindicated due to hepatotoxicity risk)
  • Risk factors for further decompensation: Albumin <3.5 g/dL, MELD >14, genotype 3
  • Expected SVR: >80% but lower than compensated cirrhosis 4

Critical warning: Glecaprevir/pibrentasvir is contraindicated in Child-Pugh B and C cirrhosis.

Practical Treatment Algorithm

Step 1: Determine cirrhosis status (imaging, elastography, or biopsy)

Step 2: If compensated or no cirrhosis, use pangenotypic regimen:

  • Sofosbuvir/velpatasvir 12 weeks (simplest, once-daily)
  • Glecaprevir/pibrentasvir 8 weeks (shortest duration for treatment-naïve without cirrhosis)

Step 3: Modify for special circumstances:

  • Genotype 3 + cirrhosis → Add ribavirin or extend duration
  • Treatment-experienced + cirrhosis → Extend glecaprevir/pibrentasvir to 12 weeks
  • Decompensated cirrhosis → Sofosbuvir + NS5A inhibitor ± ribavirin

Step 4: Monitor for sustained virologic response (SVR) at 12 weeks post-treatment 5

Key Pitfalls to Avoid

  1. Do not use protease inhibitor combinations in decompensated cirrhosis - hepatotoxicity risk 4
  2. Do not undertreat genotype 3 with cirrhosis - requires ribavirin or extended duration 1
  3. Do not use 8-week glecaprevir/pibrentasvir in treatment-experienced patients with cirrhosis - requires 12 weeks 1
  4. Do not forget ribavirin dose adjustment - weight-based: 1000 mg if <75 kg, 1200 mg if ≥75 kg 1

Treatment Success Rates

Modern DAA regimens achieve SVR12 rates of:

  • 95-99% in patients without cirrhosis 2, 1, 5
  • 90-95% in compensated cirrhosis 2, 1
  • >80% in decompensated cirrhosis 4

These rates represent a dramatic improvement over interferon-based regimens and are consistent across treatment-naïve and treatment-experienced patients when appropriate regimens are selected.

References

5
Research

Liver Disease: Hepatitis C.

FP essentials, 2021

Related Questions

In a 46-year-old male with a positive anti‑HCV antibody, HCV RNA of 2,283,553 IU/mL, normal liver function tests, normal abdominal ultrasound, and normal FibroScan, what is the appropriate management?
How should a patient with a positive anti‑HCV antibody test be evaluated and managed?
With a reactive anti‑HCV antibody screen, should I order a qualitative HCV RNA assay or a quantitative HCV RNA measurement?
What antiretroviral therapy (ART) regimen is recommended for a patient with HIV infection and decompensated chronic liver disease (Child‑Pugh class B or C)?
What is the appropriate approach to evaluate and manage a 45-year-old male with incidentally detected reactive hepatitis C virus (HCV) RNA?
How do I prescribe softclix lancets for a patient with diabetes requiring self‑monitoring of blood glucose?
When should a 24‑hour extended‑release (ER) formulation of methylphenidate be used instead of a standard extended‑release (ER) formulation?
How should post‑polio syndrome be diagnosed and managed in an adult who recovered from acute poliomyelitis and now presents with new‑onset muscle weakness, fatigue, joint pain, and respiratory difficulties?
How long after use can cocaine and methamphetamine be detected in a standard laboratory urine drug screen?
Can oxycodone be prescribed to a patient with a documented codeine allergy?
How should a 58-year-old female with depression on escitalopram (Lexapro) 20 mg daily be evaluated and managed for fatigue, loss of motivation, and worsening depressive symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.